Immunosuppression, liver injury and post-transplant HCV recurrence

Area of Science:

• Hepatology
• Transplant Immunology
• Virology

Background:

• Hepatitis C virus (HCV) infection is a leading indication for liver transplantation globally.
• Graft reinfection with HCV post-transplant is nearly universal, often causing hepatitis, fibrosis, and graft failure.
• Managing post-transplant hepatitis is complex due to multifactorial causes including rejection, drug toxicity, and other infections.

Purpose of the Study:

• To review the mechanisms of liver injury in post-transplant Hepatitis C.
• To discuss the advantages and disadvantages of immunosuppressive agents in this context.
• To explore novel strategies for preventing HCV reinfection in liver transplant recipients.

Main Methods:

• Literature review of current knowledge on HCV reinfection after liver transplantation.
• Analysis of the impact of immunosuppressive drugs on HCV replication and fibrosis.
• Synthesis of information on diagnostic challenges and therapeutic options.

Main Results:

• HCV reinfection frequently leads to graft hepatitis, fibrosis progression, and graft loss.
• Immunosuppressive drugs, particularly corticosteroids, can influence HCV infectivity and replication.
• Interferon alpha therapy has limited efficacy and tolerability in transplant recipients and may precipitate rejection.

Conclusions:

• Understanding the mechanisms of liver injury is crucial for managing post-transplant HCV.
• Careful selection and monitoring of immunosuppressive agents are necessary to balance rejection prevention and HCV control.
• Developing novel strategies to prevent HCV reinfection is essential for improving long-term outcomes in liver transplant recipients.